Delivery Order SPE2DB24D3014-SPE2DB25FKUAS
- Not listed
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $45,173.75 delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injectors on July 18, 2025, with performance completion targeted for July 21, 2025. This firm fixed-price delivery order represents a pediatric and adult immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, asthma, and eosinophilic conditions. The award was not set-aside and was competitively awarded through an open procurement...
- The Defense Logistics Agency awarded a $46,389.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen auto-injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $41,609.70 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 ml pen injectors with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $4,059.09 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of 4563942820 DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to AmerisourceBergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a $15,470.70 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products...
- The Defense Logistics Agency awarded a $16,218.65 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, firm fixed-price contract represents a pediatric or adult pharmaceutical delivery under the company's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. Dupixent (dupilumab) is a monoclonal antibody...
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at approximately $38.2K on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, firm fixed price delivery order is scheduled for completion by July 21, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUASDelivery Order
The Defense Logistics Agency awarded a $8,920.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen (2 ml) pharmaceutical supplies with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. DUPIXENT (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps. This delivery order supports the Defense Health Agency and military healthcare systems by providing this specialty pharmaceutical product through AmerisourceBergen's comprehensive pharmaceutical supply arrangement with DLA. The award reflects the company's established capability to fulfill federal medical supply requirements through open competition and demonstrates the ongoing utilization of its pharmaceutical prime vendor global contract vehicle to meet military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 7/18/25 |